Synopsis
Synopsis
0
KDMF
0
VMF
DRUG PRODUCT COMPOSITIONS0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Anaprilin
2. Anapriline
3. Avlocardyl
4. Ay 20694
5. Ay-20694
6. Ay20694
7. Betadren
8. Dexpropranolol
9. Dociton
10. Hydrochloride, Propranolol
11. Inderal
12. Obsidan
13. Obzidan
14. Propanolol
15. Propranolol
16. Rexigen
1. 318-98-9
2. Propranolol Hcl
3. Inderal
4. Avlocardyl
5. Dociton
6. Inderalici
7. Anaprilin
8. Caridolol
9. 3506-09-0
10. Berkolol
11. Herzbase
12. Indobloc
13. Naprilin
14. Pronovan
15. Pylapron
16. Sloprolol
17. Apsolol
18. Beprane
19. Deralin
20. Ikopal
21. Obsidan
22. Tesnol
23. Kemi
24. Propranolol.hcl
25. Beta Neg
26. Innopran Xl
27. Propranolol Chloride
28. Inderex
29. Nsc-91523
30. Hemangeol
31. Innopran
32. Propranolol (hydrochloride)
33. Propanolol Hydrochloride
34. Ici 45520
35. 1-(isopropylamino)-3-(1-naphthyloxy)-2-propanol Hydrochloride
36. Ay 64043
37. 1-(isopropylamino)-3-(naphthalen-1-yloxy)propan-2-ol Hydrochloride
38. Ici-45520
39. Propranolol Hydrochloride (+/-)
40. Ay-64043
41. I 2065
42. 1-naphthalen-1-yloxy-3-(propan-2-ylamino)propan-2-ol;hydrochloride
43. (s)-propranolol (hydrochloride)
44. 1-(isopropylamino)-3-(1-naphthoxy)-propan-2-ol Hydrochloride
45. (+/-)-propranolol Hydrochloride
46. F8a3652h1v
47. Hemangiol
48. Bedranol
49. Inderol
50. Pranolol
51. Sumial
52. Indermigran
53. Proprahexal
54. Propranovitan
55. Angilol
56. Arcablock
57. Artensol
58. Biocard
59. Blocaryl
60. Cardinol
61. Corbeta
62. Detensol
63. Dibudinate
64. Dumopranol
65. Efectolol
66. Emforal
67. Farprolol
68. Frekven
69. Hemipralon
70. Kidoral
71. Nelderal
72. Noloten
73. Novopranol
74. Panolol
75. Prandol
76. Propabloc
77. Propadex
78. Propalong
79. Propayerst
80. Prophylux
81. Propral
82. Propranur
83. Rapynogen
84. Sagittol
85. Sawatol
86. Scandrug
87. Sudenol
88. Tensiflex
89. Tiperal
90. Acifol
91. Cinlol
92. Ciplar
93. Elbrol
94. Herzul
95. Oposim
96. Pranix
97. Procor
98. Prosin
99. Nedis
100. Sinal
101. Tonum
102. 1-naphthalen-1-yloxy-3-(propan-2-ylamino)propan-2-ol Hydrochloride
103. 318-98-9 (hcl)
104. Half-inderal
105. Prano-puren
106. Propra Vt Ct
107. Dsstox_cid_1198
108. Inderal Hydrochloride
109. Inderal La
110. Proberta La
111. Pur-bloka
112. Beta-neg
113. Dsstox_rid_76007
114. Dsstox_gsid_21198
115. (s)-propranolol Hydrochloride
116. 1-isopropylamino-3-(1-naphthoxy)-propan-2-ol-hydrochloride
117. Dl-propranolol Hydrochloride
118. 1-(1-naphthyloxy)-2-hydroxy-3-isopropylaminopropane Hydrochloride
119. R+c5989educor
120. (+-)-1-(isopropylamino)-3-(1-naphthyloxy)-2-propanol Hydrochloride
121. 2-propanol, 1-((1-methylethyl)amino)-3-(1-naphthalenyloxy)-, Hydrochloride
122. Propraratiopharm
123. Beta-tablinen
124. Beta-timelets
125. Dl-anapriline
126. (+/-)-1-(isopropylamino)-3-(1-naphthyloxy)-2-propanol Hydrochloride
127. [2-hydroxy-3-(naphthalen-1-yloxy)propyl](propan-2-yl)amine Hydrochloride
128. 1-[(1-methylethyl)amino]-3-(naphthalen-1-yloxy)propan-2-ol Hydrochloride
129. Chebi:8500
130. Smr000059167
131. Nsc91523
132. Ccris 1105
133. Hsdb 3176
134. Sr-01000075285
135. (r)-propranolol Hydrochloride
136. Einecs 206-268-7
137. Mfcd00012558
138. D,l-propranolol Hydrochloride
139. Servanolol
140. Efektolol
141. Migrastat
142. Unii-f8a3652h1v
143. Propranolol Hydrochloride Intensol
144. Dl-propranolol Hcl
145. Relax-b
146. Einecs 222-501-5
147. Inderal (tn)
148. Nsc 91523
149. Betacap
150. Monoprolol
151. Innopran Xl (tn)
152. (r)-(+)-propanolol Hydrochloride
153. (r)-propranolol Hcl
154. Propranolol Hydrochloride [usan:usp:jan]
155. Propranolon Hydrochloride
156. 1-(isopropylamino)-3-(1-naphthyloxy)propan-2-ol Hydrochloride
157. 1-(isopropylamino)-3-(alpha-naphthoxy)-2-propanol Hydrochloride
158. Cas-318-98-9
159. Chembl1671
160. Schembl41688
161. (y)-propranolol Hydrochloride
162. Mls000859628
163. Mls001055449
164. Mls001056753
165. Mls002222321
166. Mls002548855
167. (?)-propranolol Hydrochloride
168. Spectrum1505270
169. Propranolol Hydrochloride, 99%
170. Dtxsid3021198
171. (2-hydroxy-3-(naphthyloxy)propyl)isopropylammonium Chloride
172. Hms1570p06
173. Hms1571g12
174. Hms1571i04
175. Hms1922p19
176. Pharmakon1600-01505270
177. Act02695
178. Bcp15350
179. Bcp16675
180. Eur-1000
181. Hy-b0573
182. Kdm-1102
183. Rac-propranolol Hydrochloride
184. Tox21_201886
185. Tox21_302905
186. Tox21_500896
187. 2-propanol, 1-(isopropylamino)-3-(1-naphthyloxy)-, Hydrochloride
188. Ccg-39239
189. Ccg-39447
190. Ncs-91523
191. Nsc758950
192. S4076
193. Propranalol Hydrochloride, Dl-
194. Propranolol Hydrochloride [mi]
195. 1-(naphthalen-1-yloxy)-3-[(propan-2-yl)amino]propan-2-ol Hydrochloride
196. 2-propanol, 1-(isopropylamino)-3-(1-naphthyloxy)-, Hydrochloride, (+-)-
197. Akos005267141
198. Propranolol Hydrochloride (jp17/usp)
199. (s)-2-fmoc-6-chlorhex-4-ynoic Acid
200. Ks-1097
201. Lp00896
202. Nc00687
203. Nsc-758950
204. Propranolol Hydrochloride [jan]
205. 2-propanol, 1-((1-methylethyl)amino)-3-(1-naphthalenyloxy)-, Hydrochloride, (+-)-
206. Propranolol Hydrochloride [hsdb]
207. Propranolol Hydrochloride [usan]
208. Ncgc00024690-04
209. Ncgc00091932-01
210. Ncgc00094212-01
211. Ncgc00094212-02
212. Ncgc00094212-03
213. Ncgc00094212-04
214. Ncgc00094212-05
215. Ncgc00256554-01
216. Ncgc00259435-01
217. Ncgc00261581-01
218. Propranolol Hydrochloride [mart.]
219. Propranolol Hydrochloride [vandf]
220. Propranolol Hydrochloride [usp-rs]
221. Propranolol Hydrochloride [who-dd]
222. Propranolol Hydrochloride [who-ip]
223. Db-018092
224. Eu-0100896
225. Ft-0603377
226. Ft-0635178
227. Ft-0636788
228. P0995
229. Sw219414-1
230. Wln: L66j Bo1yq1my1 & 1 & Gh
231. Bim-0050871.0001
232. D00483
233. H10708
234. P 0884
235. Propranolol Hydrochloride [ep Monograph]
236. Propranolol Hydrochloride [orange Book]
237. Propranolol Hydrochloride [usp Monograph]
238. Propranolol Hydrochloride 100 Microg/ml In Water
239. Propranololi Hydrochloridum [who-ip Latin]
240. ( Inverted Question Mark)-propranolol Hydrochloride
241. Q-201632
242. Sr-01000075285-1
243. Sr-01000075285-3
244. W-109142
245. Q27108095
246. Z90121066
247. (+/-)-propranolol Hydrochloride, >=99% (tlc), Powder
248. (+/-)-propranolol, Hydrochloride - Cas 3506-09-0
249. (+/-)-propranolol Hydrochloride, Analytical Reference Material
250. 1-(isopropylamino)-3-(1-napthyloxy)-2-propanol Hydrochloride
251. Propranolol Hydrochloride 1.0 Mg/ml In Methanol (as Free Base)
252. (+/-)-[2-hydroxy-3-(naphthyloxy)propyl]isopropylammonium Chloride
253. 1-(1-naphthyloxy)-2-hydroxy-3-(isopropylamino)propane Hydrochloride
254. 1-(1-naphthyloxy)-2-hydroxy-3-isopropylaminopropanehydrochloride
255. 1-(alpha-naphthoxy)-3-(iso-propylamino)-2-propanol Hydrochloride
256. 1-(alpha-naphthoxy)-3-(isopropylamino)-2-propanol Hydrochloride
257. 1-(isopropylamino)-3-(.alpha.-naphthoxy)-2-propanol Hydrochloride
258. Propranolol Hydrochloride, European Pharmacopoeia (ep) Reference Standard
259. ( Inverted Question Mark)-1-(isopropylamino)-3-(1-naphthyloxy)-2-propanol Hydrochloride
260. (rs)-1-[(1-methylethyl)amino]-3-(1-naphthalenyloxy)-2-propanol Hydrochloride
261. (rs)-1-[(1-methylethyl)amino]-3-(1-naphthalenyloxy)-2-propanolhydrochloride
262. Propranolol Hydrochloride, Pharmaceutical Secondary Standard; Certified Reference Material
263. Propranolol Hydrochloride, United States Pharmacopeia (usp) Reference Standard
264. 2-propanol, 1-((1-methylethyl)amino)-3-(1-naphthalenyloxy)-, Hydrochloride, (+/-)-
265. Propranolol Hydrochloride For Performance Test, European Pharmacopoeia (ep) Reference Standard
266. Propranolol Hydrochloride Solution, 1.0 Mg/ml In Methanol (as Free Base), Ampule Of 1 Ml, Certified Reference Material
| Molecular Weight | 295.80 g/mol |
|---|---|
| Molecular Formula | C16H22ClNO2 |
| Hydrogen Bond Donor Count | 3 |
| Hydrogen Bond Acceptor Count | 3 |
| Rotatable Bond Count | 6 |
| Exact Mass | 295.1339066 g/mol |
| Monoisotopic Mass | 295.1339066 g/mol |
| Topological Polar Surface Area | 41.5 Ų |
| Heavy Atom Count | 20 |
| Formal Charge | 0 |
| Complexity | 257 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 1 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 2 |
| 1 of 10 | |
|---|---|
| Drug Name | Inderal |
| PubMed Health | Propranolol (By mouth) |
| Drug Classes | Antianginal, Antiarrhythmic, Group II, Antihypertensive, Antimigraine, Cardiovascular Agent |
| Drug Label | Inderal (propranolol hydrochloride) is a synthetic beta-adrenergic receptor-blocking agent chemically described as 2-Propanol, 1-[(1-methylethyl)amino]-3-(1-naphthalenyloxy)-, hydrochloride,()-. Its molecular and structural formulae are: C16H21NO... |
| Active Ingredient | Propranolol hydrochloride |
| Dosage Form | Tablet |
| Route | oral |
| Strength | 60mg; 10mg; 80mg; 40mg; 20mg |
| Market Status | Prescription |
| Company | Akrimax Pharms |
| 2 of 10 | |
|---|---|
| Drug Name | Inderal la |
| PubMed Health | Somatropin, E coli Derived (Injection) |
| Drug Classes | Endocrine-Metabolic Agent |
| Drug Label | Inderal (propranolol hydrochloride) is a synthetic beta-adrenergic receptor-blocking agent chemically described as 2-Propanol, 1-[(1-methylethyl)amino]-3-(1-naphthalenyloxy)-, hydrochloride,()-. Its molecular and structural formulae are: C16H21NO... |
| Active Ingredient | Propranolol hydrochloride |
| Dosage Form | Capsule, extended release |
| Route | Oral |
| Strength | 160mg; 120mg; 60mg; 80mg |
| Market Status | Prescription |
| Company | Akrimax Pharms |
| 3 of 10 | |
|---|---|
| Drug Name | Innopran xl |
| PubMed Health | Propranolol |
| Drug Classes | Antianginal, Antiarrhythmic, Group II, Antihypertensive, Antimigraine, Cardiovascular Agent |
| Drug Label | INNOPRAN XL (propranolol hydrochloride) is a nonselective, beta-adrenergic receptor-blocking agent for oral administration, available as an extended release product. INNOPRAN XL is available as 80-mg and 120-mg capsules which contain sustained-releas... |
| Active Ingredient | Propranolol hydrochloride |
| Dosage Form | Capsule, extended release |
| Route | Oral |
| Strength | 120mg; 80mg |
| Market Status | Prescription |
| Company | Glaxosmithkline |
| 4 of 10 | |
|---|---|
| Drug Name | Propranolol hydrochloride |
| PubMed Health | Propranolol (Injection) |
| Drug Classes | Antianginal, Antiarrhythmic, Group II, Antihypertensive, Antimigraine, Cardiovascular Agent |
| Drug Label | hydrochloride(Propranolol is a synthetic beta-adrenergic receptor blocking agent chemically described as 2-Propanol, 1-[(1-methylethyl)amino]-3-(1-naphthalenyloxy)-, hydrochloride,()-. Its molecular and structural formulae are:C16H21NO2.HClPropr... |
| Active Ingredient | Propranolol hydrochloride |
| Dosage Form | Tablet; Injectable; Capsule, extended release; Solution |
| Route | Injection; Oral |
| Strength | 1mg/ml; 160mg; 40mg/5ml; 120mg; 60mg; 10mg; 20mg/5ml; 80mg; 40mg; 20mg |
| Market Status | Prescription |
| Company | Vintage Pharms; Upsher Smith; Bedford; Aptalis Pharmatech; Hikma Farmaceutica; Northstar Hlthcare; Sandoz; Roxane; Watson Labs; Glatt Air; Actavis Elizabeth; Baxter Hlthcare; Fresenius Kabi Usa; Ipca Labs; Zydus Pharms Usa; Pliva; Mylan |
| 5 of 10 | |
|---|---|
| Drug Name | Tev-tropin |
| Active Ingredient | Somatropin recombinant |
| Dosage Form | Injectable |
| Route | Injection |
| Strength | 5mg/vial |
| Market Status | Prescription |
| Company | Ferring |
| 6 of 10 | |
|---|---|
| Drug Name | Inderal |
| PubMed Health | Propranolol (By mouth) |
| Drug Classes | Antianginal, Antiarrhythmic, Group II, Antihypertensive, Antimigraine, Cardiovascular Agent |
| Drug Label | Inderal (propranolol hydrochloride) is a synthetic beta-adrenergic receptor-blocking agent chemically described as 2-Propanol, 1-[(1-methylethyl)amino]-3-(1-naphthalenyloxy)-, hydrochloride,()-. Its molecular and structural formulae are: C16H21NO... |
| Active Ingredient | Propranolol hydrochloride |
| Dosage Form | Tablet |
| Route | oral |
| Strength | 60mg; 10mg; 80mg; 40mg; 20mg |
| Market Status | Prescription |
| Company | Akrimax Pharms |
| 7 of 10 | |
|---|---|
| Drug Name | Inderal la |
| PubMed Health | Somatropin, E coli Derived (Injection) |
| Drug Classes | Endocrine-Metabolic Agent |
| Drug Label | Inderal (propranolol hydrochloride) is a synthetic beta-adrenergic receptor-blocking agent chemically described as 2-Propanol, 1-[(1-methylethyl)amino]-3-(1-naphthalenyloxy)-, hydrochloride,()-. Its molecular and structural formulae are: C16H21NO... |
| Active Ingredient | Propranolol hydrochloride |
| Dosage Form | Capsule, extended release |
| Route | Oral |
| Strength | 160mg; 120mg; 60mg; 80mg |
| Market Status | Prescription |
| Company | Akrimax Pharms |
| 8 of 10 | |
|---|---|
| Drug Name | Innopran xl |
| PubMed Health | Propranolol |
| Drug Classes | Antianginal, Antiarrhythmic, Group II, Antihypertensive, Antimigraine, Cardiovascular Agent |
| Drug Label | INNOPRAN XL (propranolol hydrochloride) is a nonselective, beta-adrenergic receptor-blocking agent for oral administration, available as an extended release product. INNOPRAN XL is available as 80-mg and 120-mg capsules which contain sustained-releas... |
| Active Ingredient | Propranolol hydrochloride |
| Dosage Form | Capsule, extended release |
| Route | Oral |
| Strength | 120mg; 80mg |
| Market Status | Prescription |
| Company | Glaxosmithkline |
| 9 of 10 | |
|---|---|
| Drug Name | Propranolol hydrochloride |
| PubMed Health | Propranolol (Injection) |
| Drug Classes | Antianginal, Antiarrhythmic, Group II, Antihypertensive, Antimigraine, Cardiovascular Agent |
| Drug Label | hydrochloride(Propranolol is a synthetic beta-adrenergic receptor blocking agent chemically described as 2-Propanol, 1-[(1-methylethyl)amino]-3-(1-naphthalenyloxy)-, hydrochloride,()-. Its molecular and structural formulae are:C16H21NO2.HClPropr... |
| Active Ingredient | Propranolol hydrochloride |
| Dosage Form | Tablet; Injectable; Capsule, extended release; Solution |
| Route | Injection; Oral |
| Strength | 1mg/ml; 160mg; 40mg/5ml; 120mg; 60mg; 10mg; 20mg/5ml; 80mg; 40mg; 20mg |
| Market Status | Prescription |
| Company | Vintage Pharms; Upsher Smith; Bedford; Aptalis Pharmatech; Hikma Farmaceutica; Northstar Hlthcare; Sandoz; Roxane; Watson Labs; Glatt Air; Actavis Elizabeth; Baxter Hlthcare; Fresenius Kabi Usa; Ipca Labs; Zydus Pharms Usa; Pliva; Mylan |
| 10 of 10 | |
|---|---|
| Drug Name | Tev-tropin |
| Active Ingredient | Somatropin recombinant |
| Dosage Form | Injectable |
| Route | Injection |
| Strength | 5mg/vial |
| Market Status | Prescription |
| Company | Ferring |
Adrenergic beta-Antagonists; Anti-Anxiety Agents; Anti-Arrhythmia Agents; Antihypertensive Agents; Sympatholytics; Vasodilator Agents
National Library of Medicine's Medical Subject Headings online file (MeSH, 1999)
/SRP: Former use/: Propranolol has proven to be effective in numerous cases in which digitalis, with or without quinidine and/or procainamide, failed to reduce ventricular rate, and in cases of paroxysmal atrial tachycardia attributed to digitalis toxicity.
Goodman, L.S., and A. Gilman. (eds.) The Pharmacological Basis of Therapeutics. 5th ed. New York: Macmillan Publishing Co., Inc., 1975., p. 700
Propranolol is also used in hypertrophic obstructive cardiomyopathies. In these conditions forceful contraction of myocardium along a ventricular outflow tract can greatly increase outflow resistance, particularly during exercise. .../It/ is sometimes useful in management of tachycardia and arrhythmias in patient with pheochromocytoma.
Goodman, L.S., and A. Gilman. (eds.) The Pharmacological Basis of Therapeutics. 5th ed. New York: Macmillan Publishing Co., Inc., 1975., p. 552
Medication (Vet): ...Atropine in conjunction with propranolol /was found/ to be useful in treatment of oleander poisoning.
Clarke, E.G., and M. L. Clarke. Veterinary Toxicology. Baltimore, Maryland: The Williams and Wilkins Company, 1975., p. 275
For more Therapeutic Uses (Complete) data for PROPRANOLOL HYDROCHLORIDE (25 total), please visit the HSDB record page.
.../Propranolol/ is relatively contraindicated in ...hay fever, cardiogenic shock, congestive heart failure, right ventricular failure secondary to pulmonary hypertension, and when myocardial depressant anesthetics, tricyclic antidepressants, or oral hypoglycemics are used.
Osol, A. and J.E. Hoover, et al. (eds.). Remington's Pharmaceutical Sciences. 15th ed. Easton, Pennsylvania: Mack Publishing Co., 1975., p. 835
Propranolol (1% solution) used as eye-drops .../per 1 report/, caused intense pain lasting as long as 15 min and induced hyperemia and slight miosis, but according to others these eye-drops have been well tolerated by most patients in use up to 4 times/day for 3-4 months, causing burning sensations and conjunctival hyperemia in only 8/47 eyes.
Grant, W.M. Toxicology of the Eye. 3rd ed. Springfield, IL: Charles C. Thomas Publisher, 1986., p. 768
Contraindicated in patients with cardiogenic shock, sinus bradycardia and greater than first degree block, bronchial asthma, and congestive heart failure. Adverse reactions include weakness, light headedness, depression, bradycardia, paresthesia of hands, arterial insufficiency (e.g., Raynaud type), nausea, and diarrhea. Use is best avoided in patients with bronchospastic diseases and therapy in diabetic patients must be closely monitored.
Hussar, D.A. (ed.). Modell's Drugs in Current Use and New Drugs. 38th ed. New York, NY: Springer Publishing Co., 1992., p. 140
After sudden cessation of propranolol therapy in some patients treated for angina, increased frequency, duration, and severity of angina episodes have occurred, often within 24 hr. These episodes are unstable and are not relieved by nitroglycerin. Acute and sometimes fatal myocardial infarction and sudden death have also occurred after abrupt withdrawal of propranolol therapy in some patients treated for angina. In hypertensive patients, sudden cessation of propranolol has produced a syndrome similar to florid thyrotoxicosis, characterized by tenseness, anxiety, tachycardia, and excessive perspiration; these symptoms occurred within one week of cessation of the drug and were relieved by reinstituting propranolol therapy.
McEvoy, G.K. (ed.). American Hospital Formulary Service - Drug Information 2003. Bethesda, MD: American Society of Health-System Pharmacists, Inc. 2003 (Plus Supplements)., p. 1782
For more Drug Warnings (Complete) data for PROPRANOLOL HYDROCHLORIDE (31 total), please visit the HSDB record page.
Hemangiol is indicated in the treatment of proliferating infantile haemangioma requiring systemic therapy:
- Life- or function-threatening haemangioma,
- Ulcerated haemangioma with pain and/or lack of response to simple wound care measures,
- Haemangioma with a risk of permanent scars or disfigurement.
It is to be initiated in infants aged 5 weeks to 5 months.
Adrenergic beta-Antagonists
Drugs that bind to but do not activate beta-adrenergic receptors thereby blocking the actions of beta-adrenergic agonists. Adrenergic beta-antagonists are used for treatment of hypertension, cardiac arrhythmias, angina pectoris, glaucoma, migraine headaches, and anxiety. (See all compounds classified as Adrenergic beta-Antagonists.)
Antihypertensive Agents
Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. (See all compounds classified as Antihypertensive Agents.)
Vasodilator Agents
Drugs used to cause dilation of the blood vessels. (See all compounds classified as Vasodilator Agents.)
Anti-Arrhythmia Agents
Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade. (See all compounds classified as Anti-Arrhythmia Agents.)
C07AA05
Studies in man and experimental animals indicate that rapid hepatic clearance is responsible for appearance of only trace amount of unmetabolized propranolol in blood after small oral doses. With larger doses, blood levels are linearly related to dose, suggesting saturation of hepatic metabolic system.
The Chemical Society. Foreign Compound Metabolism in Mammals Volume 3. London: The Chemical Society, 1975., p. 144
Propranolol is almost completely absorbed from the GI tract; however, plasma concentrations attained are quite variable among individuals. There is no difference in the rate of absorption of the 2 isomers of propranolol. Propranolol appears in the plasma within 30 min, and peak plasma concentrations are reached about 60-90 min after oral administration of the conventional tablets. The time when peak plasma concentrations are reached may be delayed, but concentrations are not necessarily lowered, when the drug is administered with food. Oral bioavailability of the drug may be increased in children with Down's syndrome; higher than expected plasma propranolol concentrations have been observed in such children. Bioavailability of a single 40-mg oral dose of propranolol hydrochloride as a conventional tablet or oral solution reportedly is equivalent in adults.
McEvoy, G.K. (ed.). American Hospital Formulary Service - Drug Information 2003. Bethesda, MD: American Society of Health-System Pharmacists, Inc. 2003 (Plus Supplements)., p. 1785-6
Propranolol hydrochloride is slowly absorbed following administration of the drug as extended release capsules, and peak blood concentrations are reached about 6 hr after administration. When measured at steady state over a 24 hr period, the area under the plasma concentration time curve for the extended release capsules is about 60-65% of the plasma concentration time curve for a comparable divided daily dose of the conventional tablets. The lower plasma concentration time curve is probably caused by the slower rate of absorption of the drug from the extended release capsules with resultant greater hepatic metabolism. After administration of a single dose of propranolol as the extended release capsules, blood concentrations are fairly constant for about 12 hr and then decline exponentially during the following 12 hr.
McEvoy, G.K. (ed.). American Hospital Formulary Service - Drug Information 2003. Bethesda, MD: American Society of Health-System Pharmacists, Inc. 2003 (Plus Supplements)., p. 1785-6
Following iv administration of propranolol, the onset of action is almost immediate. Animal studies indicate that propranolol is rapidly absorbed after im administration.
McEvoy, G.K. (ed.). American Hospital Formulary Service - Drug Information 2003. Bethesda, MD: American Society of Health-System Pharmacists, Inc. 2003 (Plus Supplements)., p. 1786
For more Absorption, Distribution and Excretion (Complete) data for PROPRANOLOL HYDROCHLORIDE (12 total), please visit the HSDB record page.
Besides ... 4-hydroxypropranolol and naphthoxylacetic acid, 6 new urinary metabolites have... been identified... /which are/ n-deisopropylpropranolol; 1-(alpha-naphthoxy)-2,3-propyleneglycol; ring hydroxylated 1-(alpha-naphthoxy)-2,3-propyleneglycol; alpha-naphthoxyacetic acid; alpha-naphthol and 1,4-dihydroxynaphthalene.
The Chemical Society. Foreign Compound Metabolism in Mammals Volume 3. London: The Chemical Society, 1975., p. 215
Isopropylamine and hexadeuteriated isopropylamine have been identified as urinary metabolites of propranolol and hexadeuteriated propranolol, respectively; this is believed to be 1st recorded example of single-step oxidative deamination of n-isopropylamine compound.
The Chemical Society. Foreign Compound Metabolism in Mammals Volume 3. London: The Chemical Society, 1975., p. 217
During initial oral therapy (but not during iv or chronic oral therapy), an active metabolite, 4-hydroxypropranolol, is formed. 4-Hydroxypropranolol has about the same beta-adrenergic blocking potency as does propranolol and may be present in plasma in amounts about equal to propranolol. This metabolite is eliminated more rapidly than propranolol and is virtually absent from the plasma 6 hr after oral administration of the drug. Results of one study indicate that after iv administration or chronic oral administration of propranolol, 4-hydroxypropranolol is not formed to a substantial extent, and beta-adrenergic blocking activity is more closely reflected by propranolol concentrations. Individual variations in ability to hydroxylate propranolol to the active metabolite may also exist. In addition, some other metabolites of propranolol may possess antiarrhythmic activity without beta-adrenergic blocking activity.
McEvoy, G.K. (ed.). American Hospital Formulary Service - Drug Information 2003. Bethesda, MD: American Society of Health-System Pharmacists, Inc. 2003 (Plus Supplements)., p. 1786
Propranolol is almost completely metabolized in the liver and at least 8 metabolites have been identified in urine. Only 1-4% of an oral or iv dose of the drug appears in feces as unchanged drug and metabolites.
McEvoy, G.K. (ed.). American Hospital Formulary Service - Drug Information 2003. Bethesda, MD: American Society of Health-System Pharmacists, Inc. 2003 (Plus Supplements)., p. 1786
When usual therapeutic doses of propranolol are administered chronically, the half-life ranges from 3.4-6 hr. Single dose studies generally have shown a shorter half-life of 2-3 hr.
McEvoy, G.K. (ed.). American Hospital Formulary Service - Drug Information 2003. Bethesda, MD: American Society of Health-System Pharmacists, Inc. 2003 (Plus Supplements)., p. 1786
Propranolol is a nonselective beta-adrenergic blocking agent. Propranolol inhibits response to adrenergic stimuli by competitively blocking, beta-adrenergic receptors within the myocardium and within bronchial and vascular smooth muscle. Only the l-isomer of propranolol has substantial beta-adrenergic blocking activity. Propranolol has no intrinsic sympathomimetic activity.
McEvoy, G.K. (ed.). American Hospital Formulary Service - Drug Information 2003. Bethesda, MD: American Society of Health-System Pharmacists, Inc. 2003 (Plus Supplements)., p. 1785
Through its myocardial, beta-adrenergic blocking action, propranolol decreases heart rate and prevents exercise induced increases in heart rate, decreases myocardial contractility, decreases cardiac output, increases systolic ejection time, and increases cardiac volume. The drug also decreases conduction velocity through the sinoatrial and atrioventricular nodes and decreases myocardial automaticity via beta-adrenergic blockade. At blood concentrations greater than those required for beta-adrenergic blockade, propranolol has a membrane stabilizing effect on the heart which is similar to that of quinidine. The clinical importance of this effect is not clear, but it appears to be less important than its beta-adrenergic blocking activity.
McEvoy, G.K. (ed.). American Hospital Formulary Service - Drug Information 2003. Bethesda, MD: American Society of Health-System Pharmacists, Inc. 2003 (Plus Supplements)., p. 1785
beta-Adrenergic blockade may also incr peripheral resistance initially, but peripheral resistance tends to decr after chronic admin of the drug as a result of unopposed alpha-adrenergic vasoconstriction. The cardiac effects of, beta-adrenergic blockade cause an incr in sodium reabsorption because of alterations in renal hemodynamics; renal blood flow and glomerular filtration rate generally decr during chronic therapy. Plasma volume may incr if dietary sodium is not restricted. Hepatic blood flow is decreased.
McEvoy, G.K. (ed.). American Hospital Formulary Service - Drug Information 2003. Bethesda, MD: American Society of Health-System Pharmacists, Inc. 2003 (Plus Supplements)., p. 1785
The precise mechanism of propranolol's hypotensive effect has not been determined. It has been postulated that beta-adrenergic blocking agents reduce blood pressure by blocking peripheral (especially cardiac) adrenergic receptors (decreasing cardiac output), by decreasing sympathetic outflow from the CNS, and/or by suppressing renin release. In patients with high concentrations of circulating renin, low doses of the drug are associated with a fall in both blood pressure and in plasma renin concentrations, probably because of acute peripheral beta-adrenergic blockade. With higher doses of propranolol, the hypotensive effect is probably unrelated to plasma renin activity and may be caused by a delayed centrally mediated reduction of adrenergic outflow. However, there appears to be some overlap between these mechanisms, and both mechanisms seem to be operative with usual therapeutic doses. Propranolol decreases blood pressure in both the supine and standing positions.
McEvoy, G.K. (ed.). American Hospital Formulary Service - Drug Information 2003. Bethesda, MD: American Society of Health-System Pharmacists, Inc. 2003 (Plus Supplements)., p. 1785
Through its beta-adrenergic blocking action in other body systems, propranolol increases airway resistance (especially in asthmatic patients), inhibits glycogenolysis in the skeletal and cardiac muscles, blocks the release of free fatty acids and insulin by adrenergic stimulation, and increases the number of circulating eosinophils. Propranolol increases uterine activity, more in the nonpregnant than in the pregnant uterus.
McEvoy, G.K. (ed.). American Hospital Formulary Service - Drug Information 2003. Bethesda, MD: American Society of Health-System Pharmacists, Inc. 2003 (Plus Supplements)., p. 1785
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]CEP/COS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] EU WC
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]NDC API
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us 
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]INTERMEDIATES SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Europe
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Canada
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Australia
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]DRUG PRODUCT COMPOSITIONS
DOSAGE - CAPSULE, EXTENDED RELEASE;ORAL - 120...DOSAGE - CAPSULE, EXTENDED RELEASE;ORAL - 120MG
USFDA APPLICATION NUMBER - 18553
DOSAGE - CAPSULE, EXTENDED RELEASE;ORAL - 160...DOSAGE - CAPSULE, EXTENDED RELEASE;ORAL - 160MG
USFDA APPLICATION NUMBER - 18553
DOSAGE - CAPSULE, EXTENDED RELEASE;ORAL - 60M...DOSAGE - CAPSULE, EXTENDED RELEASE;ORAL - 60MG
USFDA APPLICATION NUMBER - 18553
DOSAGE - CAPSULE, EXTENDED RELEASE;ORAL - 80M...DOSAGE - CAPSULE, EXTENDED RELEASE;ORAL - 80MG
USFDA APPLICATION NUMBER - 18553
DOSAGE - CAPSULE, EXTENDED RELEASE;ORAL - 120...DOSAGE - CAPSULE, EXTENDED RELEASE;ORAL - 120MG
USFDA APPLICATION NUMBER - 21438
DOSAGE - CAPSULE, EXTENDED RELEASE;ORAL - 80M...DOSAGE - CAPSULE, EXTENDED RELEASE;ORAL - 80MG
USFDA APPLICATION NUMBER - 21438
Related Excipient Companies
Evonik
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Rochem International Inc
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]SPI Pharma
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Seqens
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Faran Shimi Pharmaceutical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Boai NKY Pharmaceuticals Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Gangwal Healthcare
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Nanjing Well Pharmaceutical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Pfanstiehl
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]ACG Worldwide
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Actylis
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Aeon Procare
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Anhui Sunhere Pharmaceutical Excipients Co.,Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Clariant
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Corel Pharma Chem
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]DFE Pharma
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Finar
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Gangwal Chemicals
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Ideal Cures Pvt Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Ingredion Pharma Solutions
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Kerry
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Kima Chemical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Lonza Capsugel
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Microlex e.U
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Nomisma Healthcare
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Novo Excipients
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Pharmatrans-Sanaq
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Pluviaendo
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Prachin Chemical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Qianhao Chemical (Hebei) Co., Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Qualicaps
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Roquette
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Seppic
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Shanghai Shenmei Pharmaceutical Technology Co., Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Shanghai Welltone Material Technology Co., Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Shijiazhuang Huaxu Pharmaceutical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Sigachi Industries
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]The Dow Chemical Company
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Ulanqab Kema New Material
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Valens Pharmachem
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Vasa Pharmachem
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Vertellus
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Zhejiang Huakang Pharmaceutical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Excipients by Applications
Fillers, Diluents & Binders
Coating Systems & Additives
Direct Compression
Controlled & Modified Release
Disintegrants & Superdisintegrants
Thickeners and Stabilizers
Granulation
Film Formers & Plasticizers
Taste Masking
Lubricants & Glidants
Co-Processed Excipients
Solubilizers
Topical
Parenteral
Empty Capsules
Chewable & Orodispersible Aids
API Stability Enhancers
Coloring Agents
Emulsifying Agents
Rheology Modifiers
Vegetarian Capsules
Surfactant & Foaming Agents
Soft Gelatin
Digital Content
DATA COMPILATION #PharmaFlow
NEWS #PharmaBuzz
Global Sales Information
US Medicaid Prescriptions
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
USP
ANALYTICAL
Analytical Methods
ABOUT THIS PAGE
A Propranolol Hydrochloride manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Propranolol Hydrochloride, including repackagers and relabelers. The FDA regulates Propranolol Hydrochloride manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Propranolol Hydrochloride API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Propranolol Hydrochloride manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Propranolol Hydrochloride supplier is an individual or a company that provides Propranolol Hydrochloride active pharmaceutical ingredient (API) or Propranolol Hydrochloride finished formulations upon request. The Propranolol Hydrochloride suppliers may include Propranolol Hydrochloride API manufacturers, exporters, distributors and traders.
click here to find a list of Propranolol Hydrochloride suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Propranolol Hydrochloride DMF (Drug Master File) is a document detailing the whole manufacturing process of Propranolol Hydrochloride active pharmaceutical ingredient (API) in detail. Different forms of Propranolol Hydrochloride DMFs exist exist since differing nations have different regulations, such as Propranolol Hydrochloride USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Propranolol Hydrochloride DMF submitted to regulatory agencies in the US is known as a USDMF. Propranolol Hydrochloride USDMF includes data on Propranolol Hydrochloride's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Propranolol Hydrochloride USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Propranolol Hydrochloride suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Propranolol Hydrochloride Drug Master File in Japan (Propranolol Hydrochloride JDMF) empowers Propranolol Hydrochloride API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Propranolol Hydrochloride JDMF during the approval evaluation for pharmaceutical products. At the time of Propranolol Hydrochloride JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Propranolol Hydrochloride suppliers with JDMF on PharmaCompass.
A Propranolol Hydrochloride CEP of the European Pharmacopoeia monograph is often referred to as a Propranolol Hydrochloride Certificate of Suitability (COS). The purpose of a Propranolol Hydrochloride CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Propranolol Hydrochloride EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Propranolol Hydrochloride to their clients by showing that a Propranolol Hydrochloride CEP has been issued for it. The manufacturer submits a Propranolol Hydrochloride CEP (COS) as part of the market authorization procedure, and it takes on the role of a Propranolol Hydrochloride CEP holder for the record. Additionally, the data presented in the Propranolol Hydrochloride CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Propranolol Hydrochloride DMF.
A Propranolol Hydrochloride CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Propranolol Hydrochloride CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Propranolol Hydrochloride suppliers with CEP (COS) on PharmaCompass.
A Propranolol Hydrochloride written confirmation (Propranolol Hydrochloride WC) is an official document issued by a regulatory agency to a Propranolol Hydrochloride manufacturer, verifying that the manufacturing facility of a Propranolol Hydrochloride active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Propranolol Hydrochloride APIs or Propranolol Hydrochloride finished pharmaceutical products to another nation, regulatory agencies frequently require a Propranolol Hydrochloride WC (written confirmation) as part of the regulatory process.
click here to find a list of Propranolol Hydrochloride suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Propranolol Hydrochloride as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Propranolol Hydrochloride API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Propranolol Hydrochloride as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Propranolol Hydrochloride and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Propranolol Hydrochloride NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Propranolol Hydrochloride suppliers with NDC on PharmaCompass.
Propranolol Hydrochloride Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Propranolol Hydrochloride GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Propranolol Hydrochloride GMP manufacturer or Propranolol Hydrochloride GMP API supplier for your needs.
A Propranolol Hydrochloride CoA (Certificate of Analysis) is a formal document that attests to Propranolol Hydrochloride's compliance with Propranolol Hydrochloride specifications and serves as a tool for batch-level quality control.
Propranolol Hydrochloride CoA mostly includes findings from lab analyses of a specific batch. For each Propranolol Hydrochloride CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Propranolol Hydrochloride may be tested according to a variety of international standards, such as European Pharmacopoeia (Propranolol Hydrochloride EP), Propranolol Hydrochloride JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Propranolol Hydrochloride USP).
LOOKING FOR A SUPPLIER?
